Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocin prodrug
- Development stage
- Preclinical
- Lead developer
- Terran Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Terran Biosciences' psilocin prodrug program represents a portfolio of novel, orally active small-molecule prodrugs of psilocin currently in preclinical development. These compounds are designed to be metabolized into psilocin in the body, acting as agonists at the 5-HT2A receptor to produce psychedelic activity. Unlike psilocybin, the classic psilocin prodrug, Terran's compounds are engineered with modified pharmacokinetic properties to offer both shorter-acting and faster-acting profiles, aiming to reduce the duration of clinical therapy sessions and improve patient access. The program is covered under PCT patent application WO2023023347 ('Prodrugs and Derivatives of Psilocin and Uses Thereof') and is being developed for neuropsychiatric and psychiatric illnesses, including depression.
- Other names
- psilocin prodrugs
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on psilocin prodrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocin prodrug.